Earth Science Tech, Inc. (ETST) Continues Focus on
Post# of 333
(Total Views: 224)
Posted On: 06/19/2018 5:32:58 PM
Earth Science Tech, Inc. (ETST) Continues Focus on Improved Cannabis-Based Treatments
- Updates on CBD patents and medical device progress
- Working to improve medical treatments on a global scale through its subsidiaries
- Moving toward uplisting to the OTCQB Venture Market
Earth Science Tech, Inc. (OTC: ETST), based in Doral, Florida, is a biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development, including the commercialization of nutraceuticals, pharmaceuticals and medical devices. The company is working to improve medical treatments on a global scale for different diseases through its subsidiaries: Earth Science Pharmaceutical, Cannabis Therapeutics Inc., Kannabidioid Inc. and Canna Inno Laboratories Inc.
ETST is in the final phases of preparation for uplisting to the OTCQB Venture Market. This move is expected to boost investor confidence and open additional opportunities. “Transparency is a key tool that we needed to accelerate the growth of our business,” Dr. Michel Aube, CEO and chief science officer of ETST, stated in a recent news release (http://nnw.fm/6KhUm). “Since all of our amazing projects are ongoing with our partners, investor confidence will grow, and we will be able to complete our first big round of financing. We are in touch with institutional and private investors that were waiting for ETST to become a fully reporting company before investing the necessary amount to commercialize our projects. We can now resume our discussions with them.” ETST will continue to share updates on the full reporting process as it progresses.
In a recent news release (http://nnw.fm/cPK5W), the company shared updates on its ongoing CBD formula patents and medical device progress. Earlier this year, ETST announced that it received a grant from the Government of Quebec to develop three new CBD-based products. The prototyping on these products has now begun. The function of these products is to maintain quality of life and prevent inflammation, cancer and degenerative diseases. The MSN-2, a medical device developed to prevent chlamydia and other sexually transmitted infections, is in its final stage prior to the launch.
“The official launch of this medical device is a little like giving birth,” Aube stated. “It will be unique in the marketplace and we are branding this device globally. We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other Sexually Transmitted Infections.”
ETST is working with Accélération, Design et Innovation Inc. on final packaging designed to target a global audience of women, and the company is in the process of securing trademark protection for the logo and name. The device is dedicated to improving the health of women worldwide.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Updates on CBD patents and medical device progress
- Working to improve medical treatments on a global scale through its subsidiaries
- Moving toward uplisting to the OTCQB Venture Market
Earth Science Tech, Inc. (OTC: ETST), based in Doral, Florida, is a biotechnology company focused on cannabis, industrial hemp and cannabinoid research and development, including the commercialization of nutraceuticals, pharmaceuticals and medical devices. The company is working to improve medical treatments on a global scale for different diseases through its subsidiaries: Earth Science Pharmaceutical, Cannabis Therapeutics Inc., Kannabidioid Inc. and Canna Inno Laboratories Inc.
ETST is in the final phases of preparation for uplisting to the OTCQB Venture Market. This move is expected to boost investor confidence and open additional opportunities. “Transparency is a key tool that we needed to accelerate the growth of our business,” Dr. Michel Aube, CEO and chief science officer of ETST, stated in a recent news release (http://nnw.fm/6KhUm). “Since all of our amazing projects are ongoing with our partners, investor confidence will grow, and we will be able to complete our first big round of financing. We are in touch with institutional and private investors that were waiting for ETST to become a fully reporting company before investing the necessary amount to commercialize our projects. We can now resume our discussions with them.” ETST will continue to share updates on the full reporting process as it progresses.
In a recent news release (http://nnw.fm/cPK5W), the company shared updates on its ongoing CBD formula patents and medical device progress. Earlier this year, ETST announced that it received a grant from the Government of Quebec to develop three new CBD-based products. The prototyping on these products has now begun. The function of these products is to maintain quality of life and prevent inflammation, cancer and degenerative diseases. The MSN-2, a medical device developed to prevent chlamydia and other sexually transmitted infections, is in its final stage prior to the launch.
“The official launch of this medical device is a little like giving birth,” Aube stated. “It will be unique in the marketplace and we are branding this device globally. We will create a strong demand for this medical device by showing the world its powerful capacity to diminish the prevalence of chlamydia and other Sexually Transmitted Infections.”
ETST is working with Accélération, Design et Innovation Inc. on final packaging designed to target a global audience of women, and the company is in the process of securing trademark protection for the logo and name. The device is dedicated to improving the health of women worldwide.
For more information, visit the company’s website at www.EarthScienceTech.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)